Palliative care remains an underutilised treatment option in PAH. This article attempts to highlight its importance in the management of PAH and highlight the barriers faced by both physicians and patients in seeking palliative care.

Cite this article as: Khirfan G, Tonelli AR, Ramsey J, et al. Palliative care in pulmonary arterial hypertension: an underutilised treatment. Eur Respir Rev 2018; 27: 180069 [https://doi.org/10.1183/16000617.0069-2018].
they are associated with end-of-life care. This fact results in the underutilisation of palliative measures [6]. Furthermore, chronic diseases not only affect the HRQoL of patients, but also their caregivers and family members. Palliative care is a method of improving the HRQoL of both patients and caregivers when faced with incurable diseases. This entails timely intervention to 1) alleviate suffering by decreasing symptoms such as dyspnoea and pain and 2) provide a system of support oriented towards psychosocial, emotional and spiritual wellbeing [7, 8].

In spite of abundant data on the treatment of PAH [9], there is a paucity of clinical studies on the role of palliative care in the management of PAH. The important clinical implications prompted us to summarise the available evidence on the use of palliative care in patients with PAH, recognise obstacles in its utilisation and identify areas for future research.

Health-related quality of life in PAH

Pulmonary arterial hypertension imposes a significant burden on patients’ lives in many aspects, with studies showing poor HRQoL indices [3, 4, 10, 11], that might be as severe as those found in other serious and debilitating conditions such as cancer [12], interstitial lung disease [13] and spinal cord injury [14]. Pharmacological therapies for PAH alleviate patient suffering and improve HRQoL [15–20]; however, treatment-related adverse effects and parenteral routes of administration can negatively influence HRQoL [21, 22].

The overall HRQoL is measured by assessing a variety of indicators, including functional status, physical, emotional, social and spiritual wellbeing. The Pulmonary Arterial Hypertension – Symptoms and Impact (PAH-SYMPACT) questionnaire assesses disease-specific patient-reported outcomes and has recently been validated for use in PAH patients [23, 24]. This questionnaire assesses the symptoms of PAH in the previous 24 h and the impact PAH had on patients’ lives in the preceding 7 days. Table 1 shows various studies that assessed HRQoL in PAH patients and the tools used to assess it.

PAH significantly affects the physical capabilities of patients. Symptoms of shortness of breath, fatigue and exhaustion remarkably limit patients’ ability to execute activities of daily living [25]. This reduced physical activity negatively impacts HRQoL and survival [4, 26]. In addition, patients with PAH have significant psychological morbidity. In fact, the diagnosis of PAH creates emotional and psychological distress, reflected as feelings of frustration, anger, low self-esteem and worthlessness [25, 27]. Indeed, patients with worse functional class and reduced exercise capacity often have a higher prevalence of depression [10]. An observational study by McCollister et al. [10] showed that 55% of patients with PAH have depression and 15% have major depressive illness. In another study, Lowe et al. [28] found that 35% of patients with PAH suffer from psychological disorders, with the most common being depression, closely followed by panic attacks; conditions that are rarely treated. The authors found a higher prevalence of psychological symptoms in those with worse functional class. Shafazand et al. [3] reported anxiety and depression in 21% and 8% of patients with PAH, respectively. Given the high prevalence of these psychological conditions in this patient population, clinicians should be cognisant about these conditions and assess their patients during clinical encounters to prevent under-recognition and under-treatment.

Anxiety is augmented by the patients’ limited knowledge regarding PAH, including the uncertainties regarding treatment and prognosis. Many patients and caregivers resort to finding information on the internet. However, the information readily available on the web might not be current, totally accurate or applicable to the patient’s specific condition. Moreover, given that PAH is a rare condition, primary care physicians might lack adequate knowledge and/or experience to educate confidently and put patients at ease [29]. Some patients cope with these uncertainties by making memories with their loved ones and finding humour in their present setting [5].

Unexpected changes in the patients’ and caregivers’ lives contribute to the overall suffering in PAH. Worsening HRQoL in patients with PAH is associated with reduced social activity and emotional wellbeing [11]. Patients frequently face a loss of financial security and social status, as they become unable to maintain employment [10], travel obligations or social activities [25, 27]. In addition, marital relationships can suffer as sexual intimacy diminishes given physical limitations, reduced self-esteem and a partner’s fear of affecting the patient’s condition [25].

The burden of disease is not limited to patients, but also extends to caregivers. In surveys, caregivers voiced feelings of fear about losing their loved ones, as well as symptoms of stress and exhaustion as a result of the increased responsibilities of caring for them [25]. Often, the caregivers’ employment and social life is affected, contributing a decrease in the household income and overall emotional support [25]. A cross-sectional study by Hwang et al. [30] showed that 14% of caregivers of patients with PAH had to quit their jobs or reduce work hours to help provide care. The same study showed that 14% of caregivers had a Patient Health Questionnaire-8 score ≥10, suggestive of clinical depression [30].
| First author [reference] | Sample size | Patient characteristics | Tools used to assess QoL | Domains measured | Results | Comments |
|-------------------------|-------------|-------------------------|-------------------------|------------------|---------|----------|
| McCOLLISTER [24]        | n=55 in three study phases: n=25 in phase 1, n=20 in phase 2 and n=10 in phase 3 | All PAH, WHO FC I–IV | Three-phase study: a concept-elicitation phase; second phase of two rounds of cognitive interviews; a final cognitive and usability interview phase | Questionnaire assesses two domains: symptoms of PAH and impact of these symptoms on patients’ lives | Development of the PAH-SYMPACT questionnaire, which was shown to capture symptoms and its impact | CHIN et al. [23] validated the PAH-SYMPACT as the first disease-specific patient-reported outcome instrument |
| Taichman [4]            | Total n=155; completed n=55 | One-third had IPAH, WHO FC II/III | SF-36, SGRQ | SF-36 assesses physical function, bodily pain, general health, vitality and social, functional and mental health SGRQ assesses symptoms, activity and impacts (psychosocial), as well as total score | SF-36: impaired QoL in every domain SGRQ: abnormally elevated scores (indicating a worse QoL) were seen in assessments of patient symptoms, activity and the impact of disease | These scores indicate a poor physical function, mental health, increased body pain and decreased general and social wellbeing; all correlating with a lower QoL. No correlation was observed between haemodynamic measurements and QoL scores. Patients with PAH have large symptom burden that affects QoL and persist even with PAH treatment. |
| Swetz [11]              | Total n=276 | 42% with IPAH | LASA QoL items, CAMPHOR | LASA assesses physical, spiritual, emotional, intellectual and overall wellbeing CAMPHOR assesses energy, breathlessness, mood, total symptoms, function and QoL | LASA: 40% patients had score ≤5 (0 being the worst and 10 the best) CAMPHOR score centred around 50th percentile on each scale for QOL | |
| Shafazand [3]           | Total n=53 | IPAH, SSc-PAH and anorexigen-related PAH 72% in NYHA FC III or IV | NHP questionnaire, CHQ, HADS | NHP: physical mobility, pain, sleep, social isolation, emotional reactions and energy CHQ: dyspnoea, fatigue, emotional function and mastery HADS: screen for anxiety and depression | NHP: moderate to severe impairment in all domains CHQ: moderate impairment in all domains assessed HADS: moderate or severe levels of anxiety and depression were reported by 20.5% and 7.5% of participants, respectively | Impairment in multiple QoL domains, although the anxiety and depression scores were within the range of normal responses. |
| McCOLLISTER [10]        | Total n=100 | 50% had IPAH 38% had WHO FC II and 62% had FC III | PHQ-8 | PHQ-8: lack of interest, feeling of depression, energy, sleep, appetite, feeling of guilt, lack of concentration, psychomotor agitation or retardation | PHQ-8 scores showed that 15% of patients had score of ≥10, suggestive of major depression 40% had score of between 4 and 9, corresponding to mild to moderate depressive symptoms | Higher prevalence of depression disorders in PAH patients than those found in general population, patients with other medical disorders and patients with left heart failure. |

WHO: World Health Organization; FC: functional class; PAH-SYMPACT: Pulmonary Arterial Hypertension-Symptoms and Impact; IPAH: idiopathic PAH; SF-36: 36-item Short Form Health Survey; SGRQ: St George’s Respiratory Questionnaire; LASA: Linear Analogue Self-Assessment; CAMPHOR: Cambridge Pulmonary Hypertension Outcome Review; SSc: systemic sclerosis; NYHA: New York Heart Association; NHP: Nottingham Health Profile; CHQ: Congestive Heart Failure Questionnaire; HADS: Hospital Anxiety and Depression Scale; PHQ-8: Patient Health Questionnaire.
As the disease progresses, the magnitude of physical symptoms including dyspnoea, chest pain and fatigue increases [31]. With more severe symptoms, the functional class of patients declines and survival worsens [31–33]. In addition, the progression of physical symptoms is often accompanied by proportional worsening of psychological suffering and emotional distress experienced by patients and their caregivers [10, 25]. The psychological and emotional distress contributes to further decline in HRQoL. This highlights the importance of a multimodality approach to help those patients and their caregivers ease their sufferings and improve their HRQoL.

**Palliative care in PAH**

The Center to Advance Palliative Care defines palliative care as a specialised medical care for people living with serious illnesses. Palliative care is focused on providing relief from symptoms and stress caused by any chronic illness, focusing in improving the HRQoL of the patient and family. Palliative care is provided by a team of doctors, nurses and other specialists who work with the patient’s physicians to provide an extra layer of support. Palliative care is appropriate at any age or stage of disease and importantly, it must be provided in concert with curative treatment.

**Palliative care in PAH versus other serious illnesses**

In some aspects, PAH behaves like certain cancers, since PAH is a progressive disease which may lead to premature death despite the best available treatments. Some cancers, if diagnosed early, can be treated with curative intent; however, there are no curative treatments for PAH irrespective of the stage of diagnosis. Palliative care plays a significant role in cancer management, but less so in PAH. A randomised clinical trial of palliative care interventions in lung and gastrointestinal malignancies showed that early involvement of a palliative care teams improved patient and caregiver experiences [37]. Although these findings may hold true in PAH, there are still no data to support this belief.

Studies have shown that one of the barriers to referring patients with progressive lung disease for palliative medicine is the unpredictability of the disease [38]. Unlike malignancy, physicians find it hard to predict nearness of death with nonmalignant diseases that have exacerbations that alternate with periods of better control of the disease [39, 40]. When prognostic uncertainty is coupled with a cloudy understanding of the differences between palliative and hospice care, opportunities to improve patients’ HRQoL are lost [41].

Several predictors of disease severity and survival have proven to be valid in PAH, including World Health Organization (WHO) functional class, 6-min walk test (6MWT), N-terminal pro-brain natriuretic peptide (NT-proBNP), echocardiographic measures of right ventricular function and haemodynamic determinations. In addition, there are various risk assessment tools that use a combination of these measurements [9, 31–33]. These predictors of disease severity and survival help clinicians assess the prognosis and disease severity, diminishing the disease unpredictability faced in other conditions.

**Palliative therapies**

Palliative care in PAH can be broadly categorised into invasive and non-invasive. The invasive modalities of palliative care include atrial septostomy [42], right ventricular assist devices [43] and pulmonary artery...
denervation [44]. The non-invasive interventions include educating patients about their condition, providing financial assistance and information on health insurance coverage, encouraging patients to join support groups, offering spiritual support and screening for depression and providing counselling if needed [5, 10, 30]. Figure 1 summarises palliative interventions in patients with end-stage PAH.

Invasive palliative therapies

Atrial septostomy is a percutaneous procedure, by which a right-to-left shunt is created in the atrial septum, allowing decompression of the right side of the heart [45]. Several studies have shown that in the right candidates, atrial septostomy may improve symptoms, haemodynamics and potentially survival in patients with PAH [46–50] (table 2). SANDOVAL et al. [42] reported an improvement in functional class, 6-min walking distance (6MWD) and haemodynamic parameters (cardiac index and right ventricular pressure) following atrial septostomy in PAH patients. In another retrospective analysis, CHIU et al. [46]

| First author [reference] | Palliative procedure | Study design/sample size | Patient characteristics | Outcomes |
|--------------------------|----------------------|--------------------------|-------------------------|----------|
| SANDOVAL [42]            | Atrial septostomy    | Retrospective n=34       | 85% had IPAH 9% had CTEPH 53% had WHO FC IV 41% had WHO FC III 11 patients received PAH-specific therapy after procedure | 1 patient died after the procedure due to refractory hypoxaemia Improved survival in those who received PAH-specific therapy after the procedure 6MWD increased WHO FC improved mPAP and RVEDP decreased Cardiac index and LVEDP increased |
| CHIU [46]                | Atrial septostomy    | Retrospective n=32 patients No control group | All patients had PAH 63% had IPAH 78% had WHO FC III/IV All patients were receiving PAH-specific therapy after procedure | No significant change in mPAP No significant change in RAP No significant change in BNP |
| CHEN [44]                | PADN                 | Prospective n=21         | All patients had IPAH 13 underwent PADN 8 IPAH patients did not undergo PAH All were on beraprost Mean WHO FC 3.6 | Survival was not assessed Decrease in mPAP and PVR post-PADN Increase in cardiac output post-PADN Improvement in 6MWD and WHO FC |

IPAH: idiopathic pulmonary arterial hypertension; CTEPH: chronic thromboembolic pulmonary hypertension; WHO: World Health Organization; FC: functional class; 6MWD: 6-min walking distance; mPAP: mean pulmonary artery pressure; RVEDP: right ventricular end-diastolic pressure; LVEDP: left ventricular end-diastolic pressure; RAP: right atrial pressure; BNP: brain natriuretic peptide; PADN: pulmonary artery denervation; PVR: pulmonary vascular resistance.
described an improvement in symptomatic heart failure and occurrence of syncope after atrial septostomy, without significant differences in haemodynamic determinations.

Another intervention is the placement of a right ventricular assist device (RVAD). Punnoose et al. [43] modelled the cardiovascular system in simulated cases of PAH and evaluated the effects of RVAD flow rate on various haemodynamic measures. With increasing RVAD speed, there was an increase in total pulmonary blood flow, mean pulmonary artery pressure, diastolic pulmonary artery pressure, left ventricular filling pressure and cardiac output, as well as a decrease in right atrial pressure. However, this theoretical model had limitations since it reflected only the acute effect of RVAD on haemodynamics, assuming fixed pulmonary vascular resistance ventricular interactions.

Pulmonary artery denervation (PADN) involves radiofrequency ablation of sympathetic nerve fibres located at the level of the main pulmonary artery bifurcation. Chen et al. [44] used this methodology for the treatment of idiopathic PAH not responding to medical therapy. Compared to the control group, those patients with idiopathic PAH who underwent PADN had a significant reduction in mean pulmonary pressure (from 55±5 mmHg to 36±5 mmHg; p<0.01) and pulmonary vascular resistance (from 1883 dyn⋅s⋅cm⁻⁵ to 763 dyn⋅s⋅cm⁻⁵), an increase in cardiac output, improvement in the 6MWD (from 324±21 m to 491±38 m; p<0.006), Borg dyspnoea index and WHO functional class (from 3.6 to 1.6) at 3 months following the procedure. This improvement in haemodynamics and functional capacity shows that PADN might be a promising palliative procedure that needs further investigation.

In summary, the role of these invasive palliative interventions in PAH needs to be further investigated. While PADN have been shown to improve symptoms, functional class and haemodynamics in PAH patients [44], its effect in survival has not been studied and there are limited data to provide treatment recommendations. The use of RVAD in PAH also needs further investigation to better define its role [43]. Atrial septostomy has been performed as a palliative intervention in PAH in patients with end-stage PAH and sometimes as a bridge to transplant. Atrial septostomy was associated with improvement in symptoms, haemodynamics, functional class and potentially survival [42, 46, 49, 50]. However, these recommendations are based on anecdotal evidence, which again emphasises the need for further studies.

**Non-invasive palliative therapies**

Patients with PAH and their families experience physical, emotional, social and spiritual distress. The degree of physical and emotional distress is comparable or even more pronounced than patients living with cancer [35]. Interestingly, patients with PAH rate pain scores similar to patients with cancer, and symptoms of nausea almost four times higher than cancer patients [35]. With both opioid- and non-opioid-based therapies, palliative medicine physicians can work with patients towards the goal of living with less pain. Nausea can be controlled or eradicated with medications from a variety of drug classes. Fatigue and anorexia may be improved with medications to boost energy and appetite. Anxiety and depression are alleviated with medications and counselling. Counselling helps patients develop coping skills and reach peace with their “new state”. Addressing each physical symptom contributes to the patient’s global sense of wellbeing: with the goal of living with no or controlled pain or nausea, as well as higher energy and appetite, improvements that can help boost spirits and regain emotional stability. In addition, caregivers and families feel relief when the patient’s suffering is eased.

Social workers are part of every palliative care team. Social workers offer supportive listening and counsel patients and families, helping navigate changes in social status and concerns about the future. Social workers can help families with insurance and financial issues, which can seem overwhelming as family income and roles evolve as the patient’s disease progresses. Another member on the palliative care team is a pastoral counsellor. Patients with a life-limiting disease and their families struggle with questions of faith, the meaning of life and fear of the unknown. Access to a pastoral counsellor can provide a space for discussing these spiritual issues. Figure 2 shows components of the palliative care team.

While receiving palliative care, patients may receive parenteral PAH therapies under the care of their pulmonary hypertension physician. This can be at home, with home palliative medicine services until the patient reaches the point at which symptoms cannot be adequately controlled. Patients at the end of life may receive care in a hospital setting with careful consideration of patients’ and families’ expectations and goals. Tonelli et al. [1] showed that fewer than half the PAH patients who died had advance healthcare directives, and most (80%) of these deaths occurred in a healthcare setting, predominantly in the intensive care unit (52%) [1]. These results emphasise the need for a more proactive approach in discussing end-of-life care and making sure that patients with this progressive disease have time to consider options for end-of-life care. This approach helps relieve the stress and anxiety of family members who may have to make important health decisions if the patient becomes incapable of doing so.
Palliative care and lung transplant

Referral for lung transplant in PAH is recommended for patients with New York Heart Association functional class of III or IV despite maximal medical therapy, patients on parenteral prostanoids and patients with rapidly progressive disease, as evidenced by worsening 6MWT, NT-proBNP, right ventricular function and haemodynamics [51]. Patients with PAH whose mortality risk is high (estimated 1-year mortality >10%) based on comprehensive assessment of multiple variables (clinical signs of right heart failure, syncope, WHO functional class, 6MWD, NT-proBNP, cardiopulmonary exercise testing, echocardiography and haemodynamics) should be considered for lung transplantation [9]. Given the symptom burden and the sometimes prolonged waiting time for lung transplant, concomitant palliative care services are crucial to help improve HRQoL and minimise the suffering of PAH patients.

Palliative care for patients on the lung transplant waiting list involves taking care of symptoms, planning for advance care and providing emotional and spiritual support [52]. A retrospective cohort study of lung transplant candidates referred for palliative care by Colman et al. [52] showed that palliative care could be provided without harming the chances of a successful transplant. Palliative care should not be delayed until the moment when a patient is disqualified for transplantation. Pulmonary hypertension referral centre clinics should manage these end-stage patients in multidisciplinary clinics where they can get support from social workers, pastoral counsellors and palliative care physicians.

Because PAH is a progressive and life-limiting disease, palliative care involvement at an early stage in the care plan is very important, it provides an “extra layer of support” offered by a multidisciplinary palliative care team. It is important that physicians come to understand that palliative care is not the same as end-of-life care, and that palliative care is best when offered alongside life-prolonging therapies [53]. As there is a better understanding of what palliative care can offer, patients should know that a referral to palliative care is not “giving up,” but instead is an effort to thoroughly investigate all possible avenues for making quality of life the best it can be.

Conclusion

Palliative care has much to offer to patients with PAH, whose suffering extends beyond the physical realm into the psychological, spiritual and social domains. Palliative care improves functional status, exercise tolerance, haemodynamic values and viability to receive transplants. We need to better understand the reasons for the underutilisation of palliative care interventions and educate patients, caregivers and physicians on this treatment approach in order to help alleviate the suffering of patients with PAH.

Author contributions: G. Khirfan participated in literature review, collection of relevant information, writing and critical revision of the manuscript for important intellectual content and final approval of the manuscript submitted. A.R. Tonelli participated in writing and critical revision of the manuscript for important intellectual content and final

Figure 2: Structure of the palliative care team. PAH: pulmonary arterial hypertension.
approval of the manuscript submitted. J. Ramsey participated in writing and critical revision of the manuscript for important intellectual content and final approval of the manuscript submitted. S. Sahay participated in concept designing, writing and critical revision of the manuscript for important intellectual content and final approval of the manuscript submitted.

Conflict of interest: G. Khirfan has nothing to disclose. A.R. Tonelli has nothing to disclose. J. Ramsey nothing to disclose. S. Sahay has received a grant from the American College of Chest Physicians (PAH research award) and is a speaker on a panel for United Therapeutics, Actelion and Bayer pharmaceuticals.

References

1. Tonelli AR, Arelli V, Minai OA, et al. Causes and circumstances of death in pulmonary arterial hypertension. Am J Respir Crit Care Med 2013; 188: 365–369.
2. Benza RL, Miller DP, Barst RJ, et al. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL registry. Chest 2012; 142: 448–456.
3. Shafazand S, Goldstein MK, Doyle RL, et al. Health-related quality of life in patients with pulmonary arterial hypertension. Chest 2004; 126: 1452–1459.
4. Taichman DB, Shin J, Hud L, et al. Health-related quality of life in patients with pulmonary arterial hypertension. Respir Res 2005; 6: 92.
5. Flattery MP, Pinson JM, Savage L, et al. Living with pulmonary artery hypertension: patients’ experiences. Heart Lung 2005; 34: 99–107.
6. Fenstad ER, Shanafelt TD, Sloan JA, et al. Physician attitudes toward palliative care for patients with pulmonary arterial hypertension: results of a cross-sectional survey. Palm Circ 2014; 4: 504–510.
7. Centers for Medicare & Medicaid Services (CMS), HHS. Medicare and Medicaid programs: hospice conditions of participation. Final rule. Fed Regist 2008; 73: 32087–32220.
8. Rome RB, Luminias HH, Bourgeois DA, et al. The role of palliative care at the end of life. Ochser J 2011; 11: 348–352.
9. Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J 2015; 46: 903–975.
10. McCollister DH, Beutz M, McLaughlin V, et al. Depressive symptoms in pulmonary arterial hypertension: prevalence and association with functional status. Psychosomatics 2016; 51: 339–339.
11. Swetzt KM, Shanafelt TD, Drozdowicz LB, et al. Symptom burden, quality of life, and attitudes toward palliative care in patients with pulmonary arterial hypertension: results from a cross-sectional patient survey. J Heart Lung Transplant 2012; 31: 1102–1108.
12. Albertsen PC, Aaronson NK, Muller MJ, et al. Health-related quality of life among patients with metastatic prostate cancer. Urology 1997; 49: 207–216.
13. Chang JA, Curtis JR, Patrick DL, et al. Assessment of health-related quality of life in patients with interstitial lung disease. Chest 1999; 116: 1175–1182.
14. Lucke KT, Coccia H, Goode JS, et al. Quality of life in spinal cord injured individuals and their caregivers during the initial 6 months following rehabilitation. Qual Life Res 2004; 13: 97–110.
15. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996; 334: 296–301.
16. Galiè N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008; 117: 3010–3019.
17. Ghofranzi HA, Galí N, Grimminger F, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 2013; 369: 330–340.
18. Mehta S, Sastry BKS, Souza R, et al. Macitentan improves health-related quality of life for patients with pulmonary arterial hypertension: results from the randomized controlled SERAPHIN trial. Chest 2017; 151: 106–118.
19. Pepke-Zaba J, Beardsworth A, Chan M, et al. Tadalafil therapy and health-related quality of life in pulmonary arterial hypertension. Curr Med Res Opin 2009; 25: 2479–2485.
20. Pepke-Zaba J, Gilbert C, Collings L, et al. Sildenafil improves health-related quality of life in patients with pulmonary arterial hypertension. Chest 2008; 133: 183–189.
21. de Jesus Perez VA, Rosenzweig E, Rubin LJ, et al. Safety and efficacy of transition from systemic prostanooids to inhaled treprostinil in pulmonary arterial hypertension. Am J Cardiol 2012; 110: 1546–1550.
22. Rival G, Lacasse Y, Martin S, et al. Effect of pulmonary arterial hypertension-specific therapies on health-related quality of life: a systematic review. Chest 2014; 146: 686–708.
23. Chin KM, Gomberg-Maitland M, Channick RN, et al. Psychometric validation of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPTACT) questionnaire: results of the SYMPHONY trial. Chest 2018; 154: 848–861.
24. McCollister D, Shaffer S, Badesch DB, et al. Development of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPTACT*) questionnaire: a new patient-reported outcome instrument for PAH. Respir Res 2016; 17: 72.
25. Guillevin L, Armstrong I, Aldrighetti R, et al. Understanding the impact of pulmonary arterial hypertension on patients’ and carers’ lives. Eur Respir Rev 2013; 22: 535–542.
26. Ulrich S, Fischer M, Speich R, et al. Wrist actigraphy predicts outcome in patients with pulmonary hypertension. Respiration 2013; 86: 45–51.
27. Zhai Z, Zhu X, Zhang S, et al. The impact and financial burden of pulmonary arterial hypertension on patients and caregivers: results from a national survey. Medicine 2017; 96: e6783.
Löwe B, Gräfe K, Ufer C, et al. Anxiety and depression in patients with pulmonary hypertension. *Psychosom Med* 2004; 66: 831–836.

Hall H, Côté J, McBean A, et al. The experiences of patients with pulmonary arterial hypertension receiving continuous intravenous infusion of epoprostenol (Flolan) and their support persons. *Heart Lung* 2012; 41: 35–43.

Hwang B, Howie-Esquível J, Fleischmann KE, et al. Family caregiving in pulmonary arterial hypertension. *Heart Lung* 2012; 41: 26–34.

Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. *Ann Intern Med* 1987; 107: 216–223.

Benza RJ, Gomberg-Maitland M, Miller DP, et al. The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension. *Chest* 2012; 141: 354–362.

Barst RJ, Chung L, Zamanian RT, et al. Functional class improvement and 3-year survival outcomes in patients with pulmonary arterial hypertension in the REVEAL Registry. *Chest* 2013; 144: 160–168.

Saunders DC. The hospice: its meaning to patients and their physicians. *Hosp Pract* 1981; 16: 93–108.

Grinnan DC, Swetz KM, Pinson J, et al. The end-of-life experience for a cohort of patients with pulmonary arterial hypertension. *J Palliat Med* 2012; 15: 1065–1070.

Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. *Am J Respir Crit Care Med* 2002; 165: 800–804.

El-Jawhari A, Greer JA, Pirl WF, et al. Effects of early integrated palliative care on caregivers of patients with lung and gastrointestinal cancer: a randomized clinical trial. *Oncologist* 2017; 22: 1528–1534.

Lynn J, Harrell F Jr, Cohn F, et al. Prognoses of seriously ill hospitalized patients on the days before death: implications for patient care and public policy. *New Horiz* 1997; 5: 56–61.

Fox E, Landrum-McNiff K, Zhong Z, et al. Evaluation of prognostic criteria for determining hospice eligibility in patients with advanced lung, heart, or liver disease. SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments. *JAMA* 1999; 282: 1638–1645.

Terry PB. Hospice and pulmonary medicine. *Chest* 2002; 121: 11–12.

Kavalieratos D, Mitchell EM, Carey TS, et al. “Not the ‘grim reaper service’”: an assessment of provider knowledge, attitudes, and perceptions regarding palliative care referral barriers in heart failure. *J Am Heart Assoc* 2014; 3: e000544.

Sandoval J, Gaspar J, Peña H, et al. Effect of atrial septostomy on the survival of patients with severe pulmonary arterial hypertension. *Eur Respir J* 2011; 38: 1343–1348.

Punnoose L, Burkhoff D, Rich S, et al. Right ventricular assist device in end-stage pulmonary arterial hypertension: insights from a computational model of the cardiovascular system. *Prog Cardiovasc Dis* 2012; 55: 234–243.

Chen SL, Zhang FF, Xu J, et al. Pulmonary artery denervation to treat pulmonary arterial hypertension: the single-center, prospective, first-in-man PADN-1 study (first-in-man pulmonary artery denervation for treatment of pulmonary artery hypertension). *J Am Coll Cardiol* 2013; 62: 1092–1100.

Rich S, Lam W. Atrial septostomy as palliative therapy for refractory primary pulmonary hypertension. *Am J Cardiol* 1983; 51: 1560–1561.

Chiu JS, Zuckerman WA, Turner ME, et al. Balloon atrial septostomy in pulmonary arterial hypertension: effect on survival and associated outcomes. *J Heart Lung Transplant* 2015; 34: 376–380.

Velázquez Martín M, Albarrán González-Trevilla A, Jiménez López-Guarch C, et al. Use of atrial septostomy to treat severe pulmonary arterial hypertension in adults. *Rev Esp Cardiol* 2016; 69: 78–81.

Barst RJ. Role of atrial septostomy in the treatment of pulmonary vascular disease. *Thorax* 2000; 55: 95–96.

Kerstein D, Levy PS, Hsu DT, et al. Blade balloon atrial septostomy in patients with severe primary pulmonary hypertension. *Circulation* 1995; 91: 2028–2035.

Law MA, Grifka RG, Mullins CE, et al. Atrial septostomy improves survival in select patients with pulmonary hypertension. *Am Heart J* 2007; 153: 779–784.

Orens JB, Estenne M, Arcasoy S, et al. International guidelines for the selection of lung transplant candidates: 2006 update – a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. *J Heart Lung Transplant* 2006; 25: 745–755.

Colman R, Singer LG, Barua R, et al. Characteristics, interventions, and outcomes of lung transplant recipients co-managed with palliative care. *J Palliat Med* 2015; 18: 266–269.

Lindvall C, Hultman TD, Jackson VA. Overcoming the barriers to palliative care referral for patients with advanced heart failure. *J Am Heart Assoc* 2014; 3: e000742.